These clinical study results are supplied for informational purposes only in the interests of scientific disclosure. They are not intended to substitute for the FDA-approved package insert or other approved labeling. Drug Details Company Name Business Partner Drug Name Generic Name Unique ID Studied Indications or Disease Phase Approved Drug Label Shire Pharmaceuticals Adderall XR Extended release, mixed salts of a single-entity amphetamine SLI381-314A Attention-Deficit/Hyperactivity Disorder Phase III http://www.adderallxr.com/assets/pdf/prescribing_information.pdf Clinical Study Summary Efficacy and Safety of Mixed Amphetamine Salts Extended Release (Adderall XR) in the Management of Attention Deficit/Hyperactivity Disorder in Adolescent Patients: A 4-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study. T.J. Spencer, T.E. Wilens, J. Biederman et al. Clinical Therapeutics,2006:28(2):266-279. Short- and long-term cardiovascular effects of mixed amphetamine salts extended release in adolescents with ADHD. T.E. Wilens, T.J. Spencer, J. Biederman. CNS Spectr,2005;10(10 Suppl 15):22-30. http://www.clinicaltrials.gov/ct/screen/BrowseAny?path=%2Fbrowse%2Fby-sponsor%2FINDUSTRY%2FShire%2BPharmaceutical%2BDevelopment&recruiting=false You agree that access to and use of information posted by Shire on the ClinicalStudyResults.org web site is at your own risk. Shire will use reasonable efforts to post up-to-date and accurate information on this web site, but makes no warranty, condition, term, undertaking or representation (express or implied, statutory or otherwise) as to the accuracy, currency, or completeness of such information on this or any related web sites. Shire shall not under any circumstances be liable for any damages, including without limitation, direct, indirect, incidental, consequential or punitive damages, arising from access to, use of, or inability to use information posted by Shire on this web site or related sites, or any errors or omissions in its content. You should rely only on advice from your healthcare professional for your specific situation. Company Study A Phase III, Randomized, Multi-Center, Double-Blind, Parallel-Group, Placebo-Controlled Safety and Efficacy Study of ADDERALL XR, in the Treatment of Adolescents Aged 13-17 with Attention Deficit Hyperactivity Disorder (ADHD) Back to Search Results